People · Operator
Named in public records as an officer, director or promoter · active 2011–2018 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cerus Endovascular Ltd | — | Biotechnology | Series A | $8.3M | $213.7M | 2017 |
| Evenues, Inc. | — | Other | Pre-Seed | $900K | $20.8M | 2011 |
David Jennings at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Jennings on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Franklin Berger | 1 | 7 |
| J. Todd Derbin | 1 | 2 |
| Stephen J. Griffin | 1 | 2 |
| PAUL A. BROOKE | 1 | 2 |
| Sam J. Milstein | 1 | 1 |
| John J. Kilcoyne | 1 | 1 |
| TERRENCE LEE ZEHRER | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.